The present disclosure relates to medical pumps for delivering medicament to a patient and, more specifically, to user-wearable infusion pumps for delivering medicament such as insulin to a patient.
There are many applications in academic, industrial, and medical fields that benefit from devices and methods that are capable of accurately and controllably delivering fluids, such as liquids and gases, that have a beneficial effect when administered in known and controlled quantities. Such devices and methods can be particularly useful in the medical field where treatments for many patients include the administration of a known amount of a substance at predetermined intervals.
One category of devices for delivering such fluids is that of pumps that have been developed for the administration of insulin and other medicaments for those suffering from both type I and type II diabetes. Some pumps configured as portable infusion devices can provide continuous subcutaneous medicament injection and/or infusion therapy for the treatment of diabetes. Such therapy may include, e.g., the regular and/or continuous injection or infusion of insulin into the skin of a person suffering from diabetes and offer an alternative to multiple daily injections of insulin by an insulin syringe or an insulin pen. Such pumps can be ambulatory/portable infusion pumps that are worn by the user and may use replaceable cartridges. Examples of such pumps and various features that can be associated with such pumps include those disclosed in U.S. Patent Application Publication No. 2013/0053816; U.S. Pat. Nos. 8,573,027; 8,986,253; U.S. Patent Application Publication No. 2013/0324928; U.S. Patent Application Publication No. 2013/0331790; U.S. Pat. No. 8,287,495; U.S. patent application Ser. No. 15/241,257 (filed Aug. 19, 2016); and U.S. patent application Ser. No. 15/158,125 (filed May 18, 2016), each of which is hereby incorporated herein by reference in its entirety.
Many ambulatory infusion pumps are powered by batteries that need to periodically be recharged. This is typically accomplished by inserting a connector of a cable into a port on the infusion pump (such as, e.g., a USB or similar port) that facilitates the transfer of power and/or data and plugging the other end of the cable into a wall outlet or other power source. Recently, a number of consumer devices have been developed that utilize electromagnetic induction to charge an internal battery of a device without the need for additional physical electrical connections. In such systems, a transmitting induction coil within a charging base creates an alternating electromagnetic field. When a receiving induction coil in the device is aligned with the transmitting induction coil, power is transferred to the device where it is used to charge the battery. Embodiments of portable infusion pumps that utilize inductive charging are disclosed in U.S. Patent Publication No. 2016/0339172 and U.S. patent application Ser. No. 15/868,461, each of which is hereby incorporated herein by reference in its entirety.
One of the challenges in enabling inductive charging, in particular with medical devices such as ambulatory infusion pumps, is that wireless charging can cause unwanted heating in electrically conductive materials, such as metals. This heating is caused by the electromagnetic induction of eddy currents generated in the metal. Excessive heating can become a problem particularly when the transmitting and receiving coils of the charging system are not optimally aligned. Unwanted heating can cause problems for medical devices that would not be an issue for typical consumer electronic devices such as smartphones. For example, medicaments such as insulin are temperature sensitive and can degrade and/or spoil if exposed to high temperatures. The possibility therefore exists that the insulin or other medicament in an infusion pump could spoil or otherwise be rendered ineffective or even dangerous while the device is inductively charging via such excessive heating. This possibility can be particularly troublesome if the pump user or caregiver is now aware that the insulin in the interior of the pump has been so affected, especially if no damage to the exterior of the pump or its circuitry or other internal components has been experienced.
Methods and systems are disclosed wherein temperature in a device such as an ambulatory infusion pump is monitored during inductive charging of the device such that temperature-sensitive contents or components, such as, for example, insulin, particular circuitry and/or other components are not damaged. Temperature can be monitored in the device at one or more locations during inductive charging. If the temperature breaches one or more predetermined thresholds and/or is rising at a rate greater than one or more predetermined thresholds, charging can be suspended or provided at reduced power to prevent the temperature from further rising and damaging the contents and/or components of the device. One or more alerts associated with these events may also be triggered so that the user is aware of the situation and may take corrective action.
In an embodiment, a method includes detecting that an ambulatory infusion pump configured to contain a medicament and having a rechargeable battery has been placed on an inductive charging device and initiating charging of the rechargeable battery of the ambulatory infusion pump with the inductive charging device by transmitting power to the ambulatory infusion pump at a first charging rate. During charging a plurality of temperature values within the ambulatory infusion pump can be detected while power is transmitted to the ambulatory infusion pump at the first charging rate. The plurality of temperature values within the ambulatory infusion pump can be compared to a medicament sensitivity threshold temperature at which the medicament configured to be contained within the ambulatory infusion pump can become negatively affected by the temperature. If a temperature value of the plurality of temperature values within the ambulatory infusion pump is below the medicament sensitivity threshold temperature, the inductive charging device can continue to transmit power to the ambulatory infusion pump to at the first charging rate. If a temperature value of the plurality of temperature values within the ambulatory infusion pump is above the medicament sensitivity threshold temperature, the inductive charging device can reduce the first charging rate to a second charging rate lower than the first charging rate.
In an embodiment, an ambulatory infusion pump system can include an ambulatory infusion pump including a rechargeable battery and configured to contain a medicament, an inductive charging device configured to transmit power to the ambulatory infusion pump to charge the rechargeable battery of the ambulatory infusion pump and one or more processors. The system can be configured to detect that the ambulatory infusion pump has been placed on the inductive charging device and initiate charging of the rechargeable battery of the ambulatory infusion pump with the inductive charging device by transmitting power to the ambulatory infusion pump at a first charging rate. During charging a plurality of temperature values within the ambulatory infusion pump can be detected while power is transmitted to the ambulatory infusion pump at the first charging rate. The plurality of temperature values within the ambulatory infusion pump can be compared to a medicament sensitivity threshold temperature at which the medicament configured to be contained within the ambulatory infusion pump can become negatively affected by the temperature. If a temperature value of the plurality of temperature values within the ambulatory infusion pump is below the medicament sensitivity threshold temperature, the inductive charging device can continue to transmit power to the ambulatory infusion pump to at the first charging rate. If a temperature value of the plurality of temperature values within the ambulatory infusion pump is above the medicament sensitivity threshold temperature, the inductive charging device can reduce the first charging rate to a second charging rate lower than the first charging rate.
The above summary is not intended to describe each illustrated embodiment or every implementation of the subject matter hereof. The figures and the detailed description that follow more particularly exemplify various embodiments.
Subject matter hereof may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying figures, in which:
While various embodiments are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the claimed inventions to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the subject matter as defined by the claims.
In one embodiment, pump 102 includes one or more processors that control operations of the pump and, in some embodiments, may receive information and/or commands from one or more separate devices. Such a separate device can include, for example, a dedicated remote control or a smartphone or other consumer electronic device executing an application configured to enable the device to transmit operating commands to the processor of pump 102. Other separate devices may include, e.g., a continuous glucose monitor (CGM), smart pen or other device designed to provide information about a user's blood glucose values or other relevant information about the user. In some embodiments, processor can also transmit information to one or more separate devices (such as, e.g., a smartphone, smartwatch, laptop or personal computer, table computer, CGM, etc.), such as information pertaining to device parameters, alarms, reminders, pump status, etc.
Referring to
To charge the pump 102, the pump 102 may first be disconnected from the tubing of the infusion set (as depicted in
Inductive charging of pump 102 can be carried out according to known standards, such as, for example, the Qi standard. In such a system, both the pump 102 and the charging pad 180 include an inductive coil. A transmitting coil in the charging pad 180 connected to the power source generates an oscillating magnetic field that induces an alternating current in a receiving coil in the pump 102 to transfer power to pump 102. In one embodiment, charging pad 180 is continuously or periodically (e.g., twice a second) sending an analog signal to detect the presence of a pump 102. When the pad detects the presence of a pump (via a magnetic load), it sends a digital communication signal to, e.g., a processor associated with the pump 102. The pump processor receives the signal and directs and/or sends a return signal to the pad 180, which causes the pad 180 to transmit charging power to the pump.
As noted above, such inductive charging can cause unwanted heating of devices when the batteries of those devices are charged. This issue is of particular concern with regard to devices that contain one or more heat-sensitive elements, components or contents such as medical devices including, for example, ambulatory infusion pumps that deliver one or more heat-sensitive medicaments such as insulin. Embodiments of the present invention therefore incorporate one or more temperature sensors to monitor an internal temperature in medical devices such as infusion pumps and can alter and/or suspend the inductive charging based on detected temperatures.
For example, in the case of insulin it is generally known that the critical temperature for stability of insulin is around 37 degrees Celsius. The system may therefore set a threshold temperature, such as, for example, 35 degrees Celsius, at or above which action to modify inductive charging will be taken and/or instructed to prevent the insulin from reaching 37 degrees. In one embodiment, the temperature sensor or sensors do not directly measure the temperature of the insulin or other medicament, but is/are instead located on a circuit board and measure the temperature of another element, such as a piece of metal, that directly contacts the insulin reservoir of the pump. One or more temperature sensors may in addition or alternatively be located on or near other heat-sensitive components or elements (such as, e.g., particular circuitry). The system can include an internal algorithm that converts the sensed temperature to an expected temperature of the insulin or other medicament or of the component or element of interest. Thus, when the present application refers to the system determining or measuring the temperature of the insulin or other medicament, component or element, the system may actually be measuring a temperature at a different location in the pump and converting the measurement, rather than directly measuring the temperature of the insulin or other medicament, component or element. The threshold temperature is thus directly related to a temperature that can negatively affect the medicament such as insulin, rather than a temperature that might affect the electronic or other components of the system.
The system can implement one or more of a number of procedures for preventing and/or reducing high temperatures when a temperature at or exceeding the temperature threshold is detected. There may be a single temperature sensor measuring a temperature at one location in the pump or a plurality of temperature sensors measuring temperatures in a plurality of locations. When a plurality of temperature sensors are employed, an alert may be triggered when an average of the temperature measurements exceeds a threshold or when a single temperature measurement exceeds a threshold. Temperatures may be obtained by the one or more temperature sensors and/or transmitted by the processor on a continuous basis or on a periodic basis, such as, for example, once every second, once or twice every minute, etc. Although primarily described with respect to measured temperature values exceeding a set threshold value, in some embodiments a rate of change of the measured temperature value or values can alternatively or additionally be employed in a similar fashion with respect to a threshold rate of change of temperature.
In one embodiment, when the measured temperature reaches or exceeds a preset temperature threshold (or rate of change of temperature threshold), inductive charging is disabled. This can be done by the pump sending a signal to the inductive charger to suspend charging by disabling electromagnetic power from being transmitted from the charging pad to the pump. If the pump is still connected to the user and delivering medicament, the medicament delivery can also be suspended. When the temperature has dropped to an acceptable charging level, inductive charging can be reactivated. In some embodiments, suspension of inductive charging and medicament delivery and reactivation of inductive charging can be provided in an automatic closed looped fashion. Such a closed loop system may also notify a user on a user interface of the pump and/or a remote control device of one or more of the actions taken by the system. For example, an alert may be presented on a user interface notifying the user that the inductive charging and/or insulin delivery has been suspended with a follow up alert when inductive charging and/or insulin delivery has been reinstituted. Such an alert may also include an auditory and/or vibratory notification. In a further embodiment, the system may require a user confirmation in response to one or more alerts prior to taking action, such as, for example, resuming inductive charging and/or medicament delivery.
In another embodiment, rather than completely disabling inductive charging when the system is at or above the threshold temperature (or rate of change of temperature), the system can instead lower the amount of electromagnetic power being transmitted by the charging pad (i.e. the charging rate). This can be accomplished by reducing the charging rate in the pump by a predetermined amount. The charging rate can be increased once the temperature has been lowered by a desired amount. If the pump is currently delivering medicament, in some embodiments the system can disable medicament delivery when the charging rate is reduced and resume delivery when increased charging is resumed. One or more alerts may further be provided relating to the actions taken by the system. The system can, in various embodiments, undertake one or more actions automatically or may require user confirmation before undertaking one or more actions. In some embodiments, if the temperature continues to rise or is not reduced at a desired rate and/or amount, the charging rate can be further reduced or completely disabled.
Reduced charging provides the advantage over suspending charging that the device will still be continuously charged, though the temperature will not be reduced as fast under reduced charging as when charging is completely disabled. Although reduction of the charging rate has been described as an alternative to completely suspending charging, it should be understood that these two approaches could be employed together during a single charging process, in an alternating or otherwise periodically rotating manner. For example, in one embodiment charging can be reduced if the temperature exceeds a first threshold temperature and suspended if the temperature exceeds a second, higher threshold temperature. In other embodiments, suspending charging and reducing charging may be alternated or otherwise periodically rotated, as in some instances continuous reduced charging may charge the battery faster and in other instances utilizing full power charging for periods with periods of suspended charging may charge the battery faster.
One or more additional notifications may be provided to the user by the system either concurrently with or independently of the notifications of the suspension or reduction of charging and/or other notifications described herein. For example, whether charging is intermittently disabled or the charging rate is reduced, the pump will take longer than typical to charge. The user can therefore additionally be notified that the battery may take longer than expected to charge. In addition, a high temperature and/or high rate of change of temperature may indicate improper alignment of the transmitting coil in the charging pad and receiving coil in the pump. The user may therefore alternatively or additionally be notified that there may be improper alignment and to check the alignment. Repeated temperature alarms may indicate an issue with the charging pad and therefore after a threshold number of alarms the user can be notified that the charging pad may be damaged and to replace the charging pad. In addition, when the temperature has exceeded the threshold temperature and/or reach an even higher threshold (e.g., 37 degrees Celsius for insulin), the user can be notified that the insulin or other medicament may have degraded and/or spoiled. Any of the alarms and alerts described herein can further include instructions to the user to take an action with respect to the notification. For example, in various embodiments the user can be instructed to check the alignment of the pump with respect to the charging pad, use a different charging pad, etc. in conjunction with a corresponding notification.
Detailed notifications such as those described above can be provided to the user on a user interface of a device, such as, for example, the pump, a dedicated remote controller and/or a remote consumer electronic device having a software application for controlling the pump, such as a smartphone. In addition, one or more of the pump or charging pad can include an indicator light thereon. Issues with inductive charging can alternatively or additionally be indicated by such an indicator light by, for example, the light going from off to on, the light blinking, the light blinking at a different rate, the light changing color, the light brightness changing, etc. In some embodiments, different indicator light actions (e.g., different rates of blinking) can indicate different charging issues or actions (e.g., charging suspended or charging power reduced).
Although the system is primarily described herein as suspending and/or modifying an ongoing inductive charging based on temperature measurements, there may also be circumstances where the pump is initially placed on the charger at an already elevated temperature. In such circumstances, the initial charging can be reduced, not initiated, etc. and alerts provided as described herein with respect to suspension or modification of ongoing charging.
Referring now to
If it is determined that the temperature is below the predetermined threshold, either initially or after clearing an alert, full power charging is initiated to charge the device at step 214. In some embodiments, the user can be notified that charging has been initiated. During charging, the temperature can be monitored and compared to a predetermined threshold, which may be the same or different from the threshold in step 204, on a periodic or continuous basis at step 216. If the temperature is below the predetermined threshold, full power charging continues and the system continues to monitor the temperature. If the temperature is above the predetermined threshold, charging can alternatively be suspended at step 218 or continued at a reduced power at step 220. The user can be notified that charging has been suspended at step 222 or reduced at step 224, respectively, and in some embodiments can further be notified that charging has been initiated (at reduced power) at step 224. Alternatively, the corresponding action can be taken without user notification (as indicated by the dashed arrows). The system can then continue to monitor the temperature at step 216, either automatically or in response to a user confirmation, and reinitiate full power charging when the temperature falls below the predetermined temperature in response to the suspended or reduced power charging. If charging was initially reduced and the temperature either continues to increase or not lowering at a desired rate and/or amount, the charging may be further reduced or disabled. The above steps can continue until the device battery is fully charged or until the device is otherwise removed from the charger.
In embodiments, the system determinations described above can all be made by a processor of the infusion pump. For example, the infusion pump can measure the temperatures, compare the temperatures and cause the inductive charger to disable and/or modulate the transmitted power by sending control signals to the pad that cause the processor of the pad to adjust the power according to the control signal. In other embodiments, one or more of these determinations can be made by a processor of the inductive charging pad or a separate device in communication with the pump, such as a remote control device.
Although the systems and methods have primarily been described herein as applying to an infusion pump for delivering a liquid medicament such as an ambulatory insulin pump, it should be understood that the systems and methods herein can be employed with any device that can utilize inductive charging to recharge an internal battery and includes one or more heat sensitive elements.
Also incorporated herein by reference in their entirety are commonly owned U.S. Pat. Nos. 8,287,495; 8,408,421 8,448,824; 8,573,027; 8,650,937; 8,986,523; 9,173,998; 9,180,242; 9,180,243; 9,238,100; 9,242,043; 9,335,910; 9,381,271; 9,421,329; 9,486,171; 9,486,571; 9,492,608; 9,503,526; 9,555,186; 9,565,718; 9,603,995; 9,669,160; 9,715,327; 9,737,656; 9,750,871; 9,867,937; 9,867,953; 9,940,441; 9,993,595; 10,016,561; 10,201,656, commonly owned U.S. Patent Publication Nos. 2009/0287180; 2012/0123230; 2013/0053816; 2014/0276419; 2014/0276423; 2014/0276569; 2014/0276570; 2015/0182693; 2016/0082188; 2016/0339172; 2017/0049957; 2017/0142658; 2017/0182248; 2017/0250971; 2018/0021514; 2018/0071454; and 2018/0193555 and commonly owned U.S. patent application Ser. Nos. 14/707,851 and 16/266,471.
Further incorporated by reference herein in their entirety are U.S. Pat. Nos. 8,601,465; 8,502,662; 8,452,953; 8,451,230; 8,449,523; 8,444,595; 8,343,092; 8,285,328; 8,126,728; 8,117,481; 8,095,123; 7,999,674; 7,819,843; 7,782,192; 7,109,878; 6,997,920; 6,979,326; 6,936,029; 6,872,200; 6,813,519; 6,641,533; 6,554,798; 6,551,276; 6,295,506; and 5,665,065.
Various embodiments of systems, devices, and methods have been described herein. These embodiments are given only by way of example and are not intended to limit the scope of the claimed inventions. It should be appreciated, moreover, that the various features of the embodiments that have been described may be combined in various ways to produce numerous additional embodiments. Moreover, while various materials, dimensions, shapes, configurations and locations, etc. have been described for use with disclosed embodiments, others besides those disclosed may be utilized without exceeding the scope of the claimed inventions.
Persons of ordinary skill in the relevant arts will recognize that the subject matter hereof may comprise fewer features than illustrated in any individual embodiment described above. The embodiments described herein are not meant to be an exhaustive presentation of the ways in which the various features of the subject matter hereof may be combined. Accordingly, the embodiments are not mutually exclusive combinations of features; rather, the various embodiments can comprise a combination of different individual features selected from different individual embodiments, as understood by persons of ordinary skill in the art. Moreover, elements described with respect to one embodiment can be implemented in other embodiments even when not described in such embodiments unless otherwise noted.
Although a dependent claim may refer in the claims to a specific combination with one or more other claims, other embodiments can also include a combination of the dependent claim with the subject matter of each other dependent claim or a combination of one or more features with other dependent or independent claims. Such combinations are proposed herein unless it is stated that a specific combination is not intended.
Any incorporation by reference of documents above is limited such that no subject matter is incorporated that is contrary to the explicit disclosure herein. Any incorporation by reference of documents above is further limited such that no claims included in the documents are incorporated by reference herein. Any incorporation by reference of documents above is yet further limited such that any definitions provided in the documents are not incorporated by reference herein unless expressly included herein.
For purposes of interpreting the claims, it is expressly intended that the provisions of 35 U.S.C. § 112(f) are not to be invoked unless the specific terms “means for” or “step for” are recited in a claim.
The present application claims the benefit of U.S. Provisional Application No. 62/655,516 filed Apr. 10, 2018, which is hereby incorporated herein in its entirety by reference.
Number | Name | Date | Kind |
---|---|---|---|
4393365 | Kondo et al. | Jul 1983 | A |
4475901 | Kraegen et al. | Oct 1984 | A |
4678460 | Rosner | Jul 1987 | A |
5104374 | Bishko et al. | Apr 1992 | A |
5122362 | Phillips et al. | Jun 1992 | A |
5181910 | Scanlon | Jan 1993 | A |
5311175 | Waldman | May 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5364346 | Schrezenmeir | Nov 1994 | A |
5368562 | Blomquist et al. | Nov 1994 | A |
5389078 | Zalesky et al. | Feb 1995 | A |
5485408 | Blomquist | Jan 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5641405 | Keshaviah et al. | Jun 1997 | A |
5658250 | Blomquist et al. | Aug 1997 | A |
5658252 | Johnson | Aug 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5669877 | Blomquist | Sep 1997 | A |
5685844 | Marttila | Nov 1997 | A |
5690693 | Wang | Nov 1997 | A |
5695473 | Olsen | Dec 1997 | A |
5713856 | Eggers et al. | Feb 1998 | A |
5782805 | Meinzer et al. | Jul 1998 | A |
5810771 | Blomquist | Sep 1998 | A |
5814015 | Gargano et al. | Sep 1998 | A |
5822715 | Worthington et al. | Oct 1998 | A |
5876370 | Blomquist | Mar 1999 | A |
5879143 | Cote et al. | Mar 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5935106 | Olsen | Aug 1999 | A |
5997475 | Bortz | Dec 1999 | A |
6024539 | Blomquist | Feb 2000 | A |
6077055 | Vilks | Jun 2000 | A |
6122536 | Sun et al. | Sep 2000 | A |
6241704 | Peterson et al. | Jun 2001 | B1 |
6248057 | Mavity et al. | Jun 2001 | B1 |
6248067 | Causey, III et al. | Jun 2001 | B1 |
6368272 | Porumbescu | Apr 2002 | B1 |
6379301 | Worthington et al. | Apr 2002 | B1 |
6422057 | Anderson | Jul 2002 | B1 |
6475180 | Peterson et al. | Nov 2002 | B2 |
6544212 | Galley et al. | Apr 2003 | B2 |
6551276 | Mann et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6558320 | Causey, III et al. | May 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6562001 | Lebel et al. | May 2003 | B2 |
6571128 | Lebel et al. | May 2003 | B2 |
6577899 | Lebel et al. | Jun 2003 | B2 |
6582366 | Porumbescu | Jun 2003 | B1 |
6641533 | Causey, III et al. | Nov 2003 | B2 |
6648821 | Lebel et al. | Nov 2003 | B2 |
6656114 | Poulsen et al. | Dec 2003 | B1 |
6731976 | Penn et al. | May 2004 | B2 |
6740072 | Starkweather et al. | May 2004 | B2 |
6744350 | Blomquist | Jun 2004 | B2 |
6790198 | White et al. | Sep 2004 | B1 |
6809653 | Mann et al. | Oct 2004 | B1 |
6835175 | Porumbescu | Dec 2004 | B1 |
6852104 | Blomquist | Feb 2005 | B2 |
6862466 | Ackerman | Mar 2005 | B2 |
6872200 | Mann et al. | Mar 2005 | B2 |
6873268 | Lebel et al. | Mar 2005 | B2 |
6934220 | Cruitt et al. | Aug 2005 | B1 |
6936029 | Mann et al. | Aug 2005 | B2 |
6958705 | Lebel et al. | Oct 2005 | B2 |
6974437 | Lebel et al. | Dec 2005 | B2 |
6979326 | Mann et al. | Dec 2005 | B2 |
6997920 | Mann et al. | Feb 2006 | B2 |
6998387 | Goke et al. | Feb 2006 | B1 |
7025743 | Mann et al. | Apr 2006 | B2 |
7033338 | Vilks et al. | Apr 2006 | B2 |
7041082 | Blomquist et al. | May 2006 | B2 |
7098803 | Mann et al. | Aug 2006 | B2 |
7107706 | Bailey, Sr. et al. | Sep 2006 | B1 |
7109878 | Mann et al. | Sep 2006 | B2 |
7136701 | Greatbatch et al. | Nov 2006 | B2 |
7137951 | Pilarski | Nov 2006 | B2 |
7179226 | Crothall et al. | Feb 2007 | B2 |
7200504 | Fister | Apr 2007 | B1 |
7258864 | Clark | Aug 2007 | B2 |
7267665 | Steil et al. | Sep 2007 | B2 |
7276057 | Gerber | Oct 2007 | B2 |
7278983 | Ireland et al. | Oct 2007 | B2 |
7282029 | Poulsen et al. | Oct 2007 | B1 |
7291107 | Hellwig et al. | Nov 2007 | B2 |
7307245 | Faries, Jr. et al. | Dec 2007 | B2 |
7324012 | Mann et al. | Jan 2008 | B2 |
7341577 | Gill | Mar 2008 | B2 |
7354420 | Steil et al. | Apr 2008 | B2 |
7399277 | Saidara et al. | Jul 2008 | B2 |
7402153 | Steil et al. | Jul 2008 | B2 |
7404796 | Ginsberg | Jul 2008 | B2 |
7440806 | Whitehurst et al. | Oct 2008 | B1 |
7481759 | Whitehurst et al. | Jan 2009 | B2 |
7493171 | Whitehurst et al. | Feb 2009 | B1 |
7515060 | Blomquist | Apr 2009 | B2 |
7517530 | Clark | Apr 2009 | B2 |
7556841 | Kimball et al. | Jul 2009 | B2 |
7558629 | Keimel et al. | Jul 2009 | B2 |
7559926 | Blischak | Jul 2009 | B1 |
7572789 | Cowen et al. | Aug 2009 | B2 |
7651845 | Doyle, III et al. | Jan 2010 | B2 |
7678071 | Lebel et al. | Mar 2010 | B2 |
7704226 | Mueller, Jr. et al. | Apr 2010 | B2 |
7704227 | Moberg et al. | Apr 2010 | B2 |
7715893 | Kamath et al. | May 2010 | B2 |
7734323 | Blomquist et al. | Jun 2010 | B2 |
7751907 | Blomquist | Jul 2010 | B2 |
7806886 | Kanderian, Jr. et al. | Oct 2010 | B2 |
7831310 | Lebel et al. | Nov 2010 | B2 |
7869851 | Hellwig et al. | Jan 2011 | B2 |
7912674 | Killoren Clark et al. | Mar 2011 | B2 |
7935076 | Estes et al. | May 2011 | B2 |
7959598 | Estes | Jun 2011 | B2 |
7972296 | Braig et al. | Jul 2011 | B2 |
7981034 | Jennewine et al. | Jul 2011 | B2 |
7988630 | Osorio et al. | Aug 2011 | B1 |
8030802 | Lindegger et al. | Oct 2011 | B2 |
8082041 | Radziemski | Dec 2011 | B1 |
8100852 | Moberg et al. | Jan 2012 | B2 |
8119593 | Richardson et al. | Feb 2012 | B2 |
8152789 | Starkweather et al. | Apr 2012 | B2 |
8170721 | Nickerson | May 2012 | B2 |
8192394 | Estes et al. | Jun 2012 | B2 |
8192395 | Estes et al. | Jun 2012 | B2 |
8204729 | Sher | Jun 2012 | B2 |
8206350 | Mann et al. | Jun 2012 | B2 |
8206378 | Kalpin et al. | Jun 2012 | B1 |
8208984 | Blomquist et al. | Jun 2012 | B2 |
8221346 | Sakata et al. | Jul 2012 | B2 |
8226891 | Sloan et al. | Jul 2012 | B2 |
8231562 | Buck et al. | Jul 2012 | B2 |
8246540 | Ginsberg | Aug 2012 | B2 |
8287454 | Wolpert et al. | Oct 2012 | B2 |
8287495 | Michaud et al. | Oct 2012 | B2 |
8326546 | Stewart et al. | Dec 2012 | B2 |
8328754 | Estes et al. | Dec 2012 | B2 |
8348886 | Kanderian, Jr. et al. | Jan 2013 | B2 |
8348923 | Kanderian, Jr. et al. | Jan 2013 | B2 |
8376943 | Kovach et al. | Feb 2013 | B2 |
8414523 | Blomquist et al. | Apr 2013 | B2 |
8454510 | Yodfat et al. | Jun 2013 | B2 |
8457758 | Olson | Jun 2013 | B2 |
8465460 | Yodfat et al. | Jun 2013 | B2 |
8573027 | Rosinko et al. | Nov 2013 | B2 |
8938306 | Lebel | Jan 2015 | B2 |
8986253 | Lebel et al. | Jan 2015 | B2 |
9259531 | Kamen | Feb 2016 | B2 |
9381297 | Brown et al. | Jul 2016 | B2 |
9889250 | Blomquist et al. | Feb 2018 | B2 |
9974903 | Davis | May 2018 | B1 |
9993595 | Michaud et al. | Jun 2018 | B2 |
10279106 | Cook et al. | May 2019 | B1 |
10279107 | Michael | May 2019 | B2 |
10357603 | Michaud et al. | Jul 2019 | B2 |
10438696 | Shapley et al. | Oct 2019 | B2 |
10777319 | Shapley et al. | Sep 2020 | B2 |
20010031944 | Peterson et al. | Oct 2001 | A1 |
20010037217 | Abensour et al. | Nov 2001 | A1 |
20020002326 | Causey, III et al. | Jan 2002 | A1 |
20020016568 | Lebel | Feb 2002 | A1 |
20020019606 | Lebel | Feb 2002 | A1 |
20020065454 | Lebel et al. | May 2002 | A1 |
20020072733 | Flaherty | Jun 2002 | A1 |
20020072932 | Swamy | Jun 2002 | A1 |
20020096543 | Juselius | Jul 2002 | A1 |
20020107476 | Mann et al. | Aug 2002 | A1 |
20020143580 | Bristol et al. | Oct 2002 | A1 |
20020183693 | Peterson et al. | Dec 2002 | A1 |
20020193679 | Malave et al. | Dec 2002 | A1 |
20030032867 | Crothall et al. | Feb 2003 | A1 |
20030036683 | Kehr et al. | Feb 2003 | A1 |
20030050621 | Lebel et al. | Mar 2003 | A1 |
20030060765 | Campbell et al. | Mar 2003 | A1 |
20030065308 | Lebel et al. | Apr 2003 | A1 |
20030088238 | Poulsen et al. | May 2003 | A1 |
20030114836 | Estes et al. | Jun 2003 | A1 |
20030130616 | Steil et al. | Jul 2003 | A1 |
20030160683 | Blomquist | Aug 2003 | A1 |
20030163088 | Blomquist | Aug 2003 | A1 |
20030163090 | Blomquist et al. | Aug 2003 | A1 |
20030208113 | Mault et al. | Nov 2003 | A1 |
20030212364 | Mann et al. | Nov 2003 | A1 |
20030212379 | Bylund et al. | Nov 2003 | A1 |
20030225396 | Cartledge et al. | Dec 2003 | A1 |
20030236489 | Jacobson et al. | Dec 2003 | A1 |
20040015102 | Cummings et al. | Jan 2004 | A1 |
20040059295 | Cartledge et al. | Mar 2004 | A1 |
20040068230 | Estes et al. | Apr 2004 | A1 |
20040073095 | Causey, III et al. | Apr 2004 | A1 |
20040115067 | Rush et al. | Jun 2004 | A1 |
20040176720 | Kipfer | Sep 2004 | A1 |
20040180810 | Pilarski | Sep 2004 | A1 |
20040220517 | Starkweather et al. | Nov 2004 | A1 |
20040254434 | Goodnow et al. | Dec 2004 | A1 |
20050021006 | Tonnies | Jan 2005 | A1 |
20050022274 | Campbell et al. | Jan 2005 | A1 |
20050030164 | Blomquist | Feb 2005 | A1 |
20050050621 | Thomas | Mar 2005 | A1 |
20050060030 | Lashinski et al. | Mar 2005 | A1 |
20050065760 | Murtfeldt et al. | Mar 2005 | A1 |
20050085760 | Ware et al. | Apr 2005 | A1 |
20050095063 | Fathallah et al. | May 2005 | A1 |
20050137530 | Campbell et al. | Jun 2005 | A1 |
20050143864 | Blomquist | Jun 2005 | A1 |
20050171513 | Mann et al. | Aug 2005 | A1 |
20050177137 | Kipfer | Aug 2005 | A1 |
20050197553 | Cooper | Sep 2005 | A1 |
20050197621 | Poulsen et al. | Sep 2005 | A1 |
20050277872 | Colby, Jr. et al. | Dec 2005 | A1 |
20060001550 | Mann et al. | Jan 2006 | A1 |
20060014670 | Green et al. | Jan 2006 | A1 |
20060047192 | Hellwig et al. | Mar 2006 | A1 |
20060047538 | Condurso et al. | Mar 2006 | A1 |
20060080059 | Stupp et al. | Apr 2006 | A1 |
20060122577 | Poulsen et al. | Jun 2006 | A1 |
20060132292 | Blomquist | Jun 2006 | A1 |
20060137695 | Hellwig et al. | Jun 2006 | A1 |
20060149220 | Ullestad et al. | Jul 2006 | A1 |
20060173406 | Hayes et al. | Aug 2006 | A1 |
20060173444 | Choy et al. | Aug 2006 | A1 |
20060202859 | Mastrototaro et al. | Sep 2006 | A1 |
20060224109 | Steil et al. | Oct 2006 | A1 |
20060253097 | Braig et al. | Nov 2006 | A1 |
20060264895 | Flanders | Nov 2006 | A1 |
20060276771 | Galley et al. | Dec 2006 | A1 |
20070016127 | Staib et al. | Jan 2007 | A1 |
20070016449 | Cohen et al. | Jan 2007 | A1 |
20070021733 | Hansen et al. | Jan 2007 | A1 |
20070033074 | Nitzan et al. | Feb 2007 | A1 |
20070060796 | Kim | Mar 2007 | A1 |
20070060871 | Istoc et al. | Mar 2007 | A1 |
20070061735 | Hoffberg et al. | Mar 2007 | A1 |
20070066956 | Finkel | Mar 2007 | A1 |
20070100222 | Mastrototaro et al. | May 2007 | A1 |
20070106135 | Sloan et al. | May 2007 | A1 |
20070112299 | Smit et al. | May 2007 | A1 |
20070124002 | Estes et al. | May 2007 | A1 |
20070156033 | Causey, III et al. | Jul 2007 | A1 |
20070203454 | Shermer et al. | Aug 2007 | A1 |
20070219480 | Kamen et al. | Sep 2007 | A1 |
20070219496 | Kamen et al. | Sep 2007 | A1 |
20070219597 | Kamen et al. | Sep 2007 | A1 |
20070228071 | Kamen et al. | Oct 2007 | A1 |
20070233051 | Hohl et al. | Oct 2007 | A1 |
20070239096 | Keenan et al. | Oct 2007 | A1 |
20070255250 | Moberg et al. | Nov 2007 | A1 |
20080004601 | Jennewine et al. | Jan 2008 | A1 |
20080017194 | Hassanein et al. | Jan 2008 | A1 |
20080030369 | Mann et al. | Feb 2008 | A1 |
20080033357 | Mann et al. | Feb 2008 | A1 |
20080051709 | Mounce et al. | Feb 2008 | A1 |
20080051714 | Moberg et al. | Feb 2008 | A1 |
20080071251 | Moubayed et al. | Mar 2008 | A1 |
20080071580 | Marcus et al. | Mar 2008 | A1 |
20080097289 | Steil et al. | Apr 2008 | A1 |
20080106431 | Blomquist | May 2008 | A1 |
20080125700 | Moberg et al. | May 2008 | A1 |
20080125701 | Moberg et al. | May 2008 | A1 |
20080147050 | Mann et al. | Jun 2008 | A1 |
20080172026 | Blomquist | Jul 2008 | A1 |
20080172027 | Blomquist | Jul 2008 | A1 |
20080172028 | Blomquist | Jul 2008 | A1 |
20080172029 | Blomquist | Jul 2008 | A1 |
20080172030 | Blomquist | Jul 2008 | A1 |
20080172031 | Blomquist | Jul 2008 | A1 |
20080177165 | Blomquist et al. | Jul 2008 | A1 |
20080183060 | Steil et al. | Jul 2008 | A1 |
20080206799 | Blomquist | Aug 2008 | A1 |
20080228056 | Blomquist et al. | Sep 2008 | A1 |
20080262378 | Gerber et al. | Oct 2008 | A1 |
20080262380 | Gerber et al. | Oct 2008 | A1 |
20080262878 | Gerber et al. | Oct 2008 | A1 |
20080269585 | Ginsberg | Oct 2008 | A1 |
20080281297 | Pesach et al. | Nov 2008 | A1 |
20080287922 | Panduro | Nov 2008 | A1 |
20080294024 | Cosentino | Nov 2008 | A1 |
20080294294 | Blomquist | Nov 2008 | A1 |
20080300534 | Blomquist | Dec 2008 | A1 |
20080300572 | Rankers et al. | Dec 2008 | A1 |
20080306353 | Douglas et al. | Dec 2008 | A1 |
20080312723 | Gill et al. | Dec 2008 | A1 |
20090005724 | Regittnig | Jan 2009 | A1 |
20090005726 | Jones et al. | Jan 2009 | A1 |
20090018779 | Cohen et al. | Jan 2009 | A1 |
20090030733 | Cohen et al. | Jan 2009 | A1 |
20090036753 | King | Feb 2009 | A1 |
20090069749 | Miller et al. | Mar 2009 | A1 |
20090069787 | Estes et al. | Mar 2009 | A1 |
20090088731 | Campbell et al. | Apr 2009 | A1 |
20090105646 | Hendrixson et al. | Apr 2009 | A1 |
20090112626 | Talbot et al. | Apr 2009 | A1 |
20090131860 | Nielsen | May 2009 | A1 |
20090131861 | Braig et al. | May 2009 | A1 |
20090150186 | Cohen et al. | Jun 2009 | A1 |
20090177142 | Blomquist et al. | Jul 2009 | A1 |
20090177147 | Blomquist et al. | Jul 2009 | A1 |
20090177154 | Blomquist | Jul 2009 | A1 |
20090212966 | Panduro | Aug 2009 | A1 |
20090240193 | Mensinger et al. | Sep 2009 | A1 |
20090254037 | Bryant, Jr. et al. | Oct 2009 | A1 |
20100056993 | Chase | Mar 2010 | A1 |
20100057043 | Kovatchev et al. | Mar 2010 | A1 |
20100114015 | Kanderian, Jr. et al. | May 2010 | A1 |
20100121415 | Skelton et al. | May 2010 | A1 |
20100138197 | Sher | Jun 2010 | A1 |
20100145262 | Bengtsson et al. | Jun 2010 | A1 |
20100145303 | Yodfat et al. | Jun 2010 | A1 |
20100152644 | Pesach et al. | Jun 2010 | A1 |
20100152811 | Flaherty | Jun 2010 | A1 |
20100156633 | Buck, Jr. et al. | Jun 2010 | A1 |
20100174266 | Estes | Jul 2010 | A1 |
20100198142 | Sloan et al. | Aug 2010 | A1 |
20100198520 | Breton et al. | Aug 2010 | A1 |
20100218132 | Soni et al. | Aug 2010 | A1 |
20100222765 | Blomquist et al. | Sep 2010 | A1 |
20100262117 | Magni et al. | Oct 2010 | A1 |
20100262434 | Shaya | Oct 2010 | A1 |
20100274592 | Nitzan et al. | Oct 2010 | A1 |
20100274751 | Blomquist | Oct 2010 | A1 |
20100292634 | Kircher, Jr. et al. | Nov 2010 | A1 |
20100295686 | Sloan et al. | Nov 2010 | A1 |
20100305545 | Kanderian, Jr. et al. | Dec 2010 | A1 |
20100312085 | Andrews et al. | Dec 2010 | A1 |
20100324382 | Cantwell et al. | Dec 2010 | A1 |
20110009824 | Yodfat et al. | Jan 2011 | A1 |
20110021898 | Wei et al. | Jan 2011 | A1 |
20110033833 | Blomquist et al. | Feb 2011 | A1 |
20110040247 | Mandro et al. | Feb 2011 | A1 |
20110040251 | Blomquist et al. | Feb 2011 | A1 |
20110046697 | Gerber et al. | Feb 2011 | A1 |
20110047499 | Mandro et al. | Feb 2011 | A1 |
20110053121 | Heaton | Mar 2011 | A1 |
20110054390 | Searle et al. | Mar 2011 | A1 |
20110058485 | Sloan | Mar 2011 | A1 |
20110071765 | Yodfat et al. | Mar 2011 | A1 |
20110092788 | Long et al. | Apr 2011 | A1 |
20110098548 | Budiman et al. | Apr 2011 | A1 |
20110106011 | Cinar et al. | May 2011 | A1 |
20110106050 | Yodfat et al. | May 2011 | A1 |
20110112505 | Starkweather et al. | May 2011 | A1 |
20110112506 | Starkweather et al. | May 2011 | A1 |
20110125095 | Lebel et al. | May 2011 | A1 |
20110160695 | Sigrist et al. | Jun 2011 | A1 |
20110172744 | Davis et al. | Jul 2011 | A1 |
20110178717 | Goodnow et al. | Jul 2011 | A1 |
20110190701 | Remde et al. | Aug 2011 | A1 |
20110196213 | Thukral et al. | Aug 2011 | A1 |
20110205065 | Strachan et al. | Aug 2011 | A1 |
20110208155 | Palerm et al. | Aug 2011 | A1 |
20110238033 | Prod et al. | Sep 2011 | A1 |
20110257591 | Nelson Konen | Oct 2011 | A1 |
20120041415 | Estes et al. | Feb 2012 | A1 |
20120059353 | Kovatchev et al. | Mar 2012 | A1 |
20120059673 | Cohen et al. | Mar 2012 | A1 |
20120078181 | Smith et al. | Mar 2012 | A1 |
20120184907 | Smith | Jul 2012 | A1 |
20120185267 | Kamen et al. | Jul 2012 | A1 |
20120191061 | Yodfat et al. | Jul 2012 | A1 |
20120191063 | Brauker et al. | Jul 2012 | A1 |
20120209165 | Degen et al. | Aug 2012 | A1 |
20120232520 | Sloan et al. | Sep 2012 | A1 |
20120302991 | Blomquist et al. | Nov 2012 | A1 |
20130046281 | Javitt | Feb 2013 | A1 |
20130053816 | Diperna et al. | Feb 2013 | A1 |
20130238048 | Almendinger | Sep 2013 | A1 |
20130324928 | Kruse | Dec 2013 | A1 |
20130331790 | Brown et al. | Dec 2013 | A1 |
20140012511 | Mensinger et al. | Jan 2014 | A1 |
20140070761 | Labbe | Mar 2014 | A1 |
20140187890 | Mensinger | Jul 2014 | A1 |
20140266022 | Degen et al. | Sep 2014 | A1 |
20140323961 | Blomquist et al. | Oct 2014 | A1 |
20150196709 | Jacobson et al. | Jul 2015 | A1 |
20160213843 | Despa | Jul 2016 | A1 |
20160339172 | Michaud et al. | Nov 2016 | A1 |
20170049957 | Michaud | Feb 2017 | A1 |
20170142658 | Kruse | May 2017 | A1 |
20190190296 | Paralikar | Jun 2019 | A1 |
Number | Date | Country |
---|---|---|
4407005 | Mar 1995 | DE |
10121317 | Nov 2002 | DE |
10352456 | Jul 2005 | DE |
1102194 | May 2001 | EP |
1571582 | Sep 2005 | EP |
1904153 | Apr 2015 | EP |
WO-0045696 | Aug 2000 | WO |
WO-0074753 | Dec 2000 | WO |
WO-0152727 | Jul 2001 | WO |
WO-02062212 | Aug 2002 | WO |
WO-2005018507 | Mar 2005 | WO |
WO-2005046559 | May 2005 | WO |
WO-2006061169 | Jun 2006 | WO |
WO-2007000425 | Jan 2007 | WO |
WO-2007056592 | May 2007 | WO |
WO-2007089537 | Aug 2007 | WO |
WO-2007149533 | Dec 2007 | WO |
WO-2008048556 | Apr 2008 | WO |
WO-2008048582 | Apr 2008 | WO |
WO-2008048583 | Apr 2008 | WO |
WO-2008048584 | Apr 2008 | WO |
WO-2008048585 | Apr 2008 | WO |
WO-2008048586 | Apr 2008 | WO |
WO-2008048587 | Apr 2008 | WO |
WO-2008091320 | Jul 2008 | WO |
WO-2008112078 | Sep 2008 | WO |
WO-2008153689 | Dec 2008 | WO |
WO-2008153819 | Dec 2008 | WO |
WO-2009035759 | Mar 2009 | WO |
WO-2009088983 | Jul 2009 | WO |
WO-2009089028 | Jul 2009 | WO |
WO-2009089029 | Jul 2009 | WO |
WO-2010096449 | Aug 2010 | WO |
Entry |
---|
Application and File history for U.S. Patent Application No. U.S. Appl. No. 14/317,751, filed Jun. 27, 2014 . . . Inventors: Blomquist et al. |
Search report and Written Opinion dated Jul. 15, 2019 for PCT Application No. PCT/US2019/26765, 10 pages. |
Bott, et al., “Impact of Smoking on the Metabolic Action of Subcutaneous Regular Insulin in Type 2 Diabetic Patients,” Horm. Metab. Res., vol. 37, 2005, pp. 445-449. |
Chase, et at., “The Use of Insulin Pumps With Meal Bolus Alarms in Children With Type 1 Diabetes to Improve Glycemic Control,” Diabetes Carem, vol. 29, No. 5, May 2006, pp. 1012-1015. |
“Compare Insulin Pump for Diabetes,” Printed from www.diabetesnet.com/diabetes-technology/insulin-pump-models.php, Jun. 18, 2009, 4 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US09/00107 dated May 4, 2009, 9 pages. |
Lehmann, et al., “Combining rule-based reasoning and mathematical modeling in diabetes care,” Artificial Intelligence in Medicine, vol. 6, 1994, pp. 137-160. |
Hildebrandt P, “Subcutaneous Absorption of Insulin in Insulin-Dependent Diavetic patients. Influence of Species Physico-Chemical properties of Insulin and Physiological factors,” Danish Medical Bulletin, Aug. 1991, 10 pages. |
Plougmann, et al., “DiasNet—a diabetes advisory system for communication and education via the internet,” International Journal of Medical Informatics, vol. 64, 2001, 1 page. |
Puckett, et al., “A model for multiple subcutaneous insulin injections developed from individual diabetic patient data,” vol. 269, 1995, p. E1115-E1124. |
Smith Medical MD Inc., “Deltec Cozmo, Personalized Insulin Pump, Starting Guide,” http://web.archive.org/web/20041207133223/http://www.cozmore.com/Library/-upload/starting.sub.--guide.sub.--032004.pdf, XP002497833, Dec. 7, 2004, pp. 1-83. |
Stapel E., “Converting Between Decimals, Fractions, and Percents,” Purplemath, 2006, 9 pages, Available at http://www.purplemath.com/modules/percents2.htm, 2006. |
Trajanoski, et al., “Pharmacokinetic Model for the Absorption of Subcutaneously Injected Soluble Insulin and Monomeric Insulin Analogues,” Biomedizinische Technik, vol. 38, No. 9. Sep. 1, 1993, pp. 224-231. |
Wach, et al., “Numerical Approximation of Mathematical Model for Absorption of Subcutaneously Injected Insulin,” Med & Biol. Eng & comput., vol. 33, 1995, pp. 18-23. |
Walsh, et al., “Diabetes Technology—Concept 1: Super Bolus, available at Diabetes Technology—Concept 1: Super Bolus” available at http://www.diabetesnet.com/diabetes.sub.--technology/super.sub.--bolus.ph-p>, Sep. 17, 2007, 3 pages. |
Walsh J., et al., “Select & Test Your Correction Factor,” Pumping Insulin, Fourth Edition, Chapter 13, 2006, 10 Pages. |
Walsh J., et al., “Select & Test Your Basal Rates,” Pumping Insulin, Fourth Edition, Chapter 11, 2006, 30 pages. |
Walsh J., et al., “Select and Test Your Carb Factor,” Pumping Insulin, Fourth Edition, Chapter 12, 2006, 32 pages. |
Walsh J., et al., “Pumping Insulin: Everything you need for Success on a Smart insulin Pump,” Torrey Pines Press, San Diego, ISBN 1-884804-86-1, 2006, 3 pages. |
wikipedia.com, “Wikipedia's definition for “basal rate”,” printed from wikipedia.com on Jun. 12, 2009, 1 page. |
Wilinska, et al., “Insulin Kinetics in Type-1 Diabetes: Continuous and Bolus Delivery of Rapid Acting Insulin,” IEEE Transactions on Biomedical Engineering, vol. 52, No. 1, Jan. 2005, pp. 3-12. |
EP Application No. 19785688.3, Extended EP Search Report dated Nov. 22, 2021, 11 pages. |
Number | Date | Country | |
---|---|---|---|
20190307952 A1 | Oct 2019 | US |
Number | Date | Country | |
---|---|---|---|
62655516 | Apr 2018 | US |